Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Inactivated Quadrivalent Influenza Vaccine in Children Aged 3-8 Years
NCT05313893Phase 4Completed
- Sponsor
- Jiangsu Provincial Center for Disease Control and Prevention
- Start
- Sep 2021
- Primary completion
- Dec 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of quadrivalent influenza vaccine in influenza, sponsored by Jiangsu Provincial Center for Disease Control and Prevention. Primary endpoints: Seroconversion Rate and Number of participants with Adverse Reactions. Started Sep 2021; status: completed.
02
Drugs
quadrivalent influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05313893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05313893.